摘要
目的 观察那格列奈对 2型糖尿病 (T2DM )的临床疗效。方法 4 8例 2型糖尿病患者随机分为那格列奈组和瑞格列奈组 ,治疗 12周后采用氧化酶法测定空腹血浆葡萄糖 (FPG)、餐后 2h血浆葡萄糖 (2hPG)和DiaSTAT测定仪及配套试剂盒测定糖化血红蛋白A1c(HbA1c)比较其临床疗效。结果 那格列奈组治疗后FPG、2hPG和HbA1c水平均下降 (P <0 0 0 1) ,与治疗前相比分别下降 (1 37± 1 33)mmol/L、(5 14± 2 0 5 )mmol/L、(0 6 0± 0 36 ) % ,与瑞格列奈组差异无显著性 ;那格列奈组病例未发现明显药物副反应 ,主要实验室检查无异常改变。结论 那格列奈疗效肯定 ,副反应发生率低且耐受性良好。
Objective To observe the efficacy and safety of nateglinide in the treatment of type 2 diabetic patients. Methods 48 cases of type 2 diabetic patients were randomly assigned to nateglinide ( n =24) or repaglinide ( n =24) treatment group, and measured the fasting plasma glucose (FPG) and 2 hours postprandial plasma glucose (2 h PG) by oxidase and measure HbA1c by DiaSTAT rediomete , compared the efficacy of two groups after treated for 12 weeks. Results After treated by naleglinide 12 weeks, FPG and 2 h PG and HbA1c levels were significantly decreased ( P <0 001) when compared to the baseline, the reduced values of FPG, 2 h PG and HbA1c were (1 37±1 33) mmol/L, (5 14±2 05) mmol/L and (0 60±0 36)%, respectively, the differences between the groups were not statistically significant. The side effect of nateglinide group was not observed and the main laboratory parameters did not change significantly after treatment in nateglinide group. Conclusion These results provide an efficacy of nateglinide in glycemic control and a safety profile of nateglinide in the treatment of type 2 diabetes mellitus.
出处
《安徽医科大学学报》
CAS
2003年第6期458-460,共3页
Acta Universitatis Medicinalis Anhui
关键词
那格列奈
药物治疗
2型糖尿病
瑞格列奈
diabetes mellitus, non insulin dependent
drug therapy, hypoglycemic agents/therapeutic use
